Aurinia制药 AUPH 深 沪
等待开盘 05-20 09:30:00 美东时间
15.55
-0.050
-0.32%
华盛通- 最 高15.73
- 今 开15.58
- 成交量 77.56万股
- 最 低 15.38
- 昨 收 15.60
- 总市值 20.00亿
- 52周最高 16.88
- 市盈率 静 7.51
- 换手率 0.00%
- 52周最低 7.285
- 委 比 36.29%
- 总股本 1.29亿
- 历史最高 33.972
- 量 比 0.65
- 振 幅 2.24%
- 历史最低 1.41
- 每 手 1
- 风险率 2.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Aurinia Pharmaceuticals Completes Acquisition of Kezar Life Sciences
Aurinia Pharmaceuticals ( ($AUPH) ) just unveiled an update. On May 8, 2026, Au...
05-11 21:59
Aurinia Pharmaceuticals shares are trading lower. The company reported Q1 financial results and affirmed FY26 sales guidance below estimates.
Aurinia Pharmaceuticals shares are trading lower. The company reported Q1 finan...
05-07 22:38
Aurinia Pharmaceuticals Affirms FY2026 Sales Guidance of $315.000M-$325.000M vs $326.190M Est
Aurinia Pharmaceuticals (NASDAQ:AUPH) affirms FY2026 sales outlook from $315.000 million-$325.000 million to $315.000 million-$325.000 million vs $326.190 million estimate.
05-07 21:36
Aurinia Pharmaceuticals Q1 EPS $0.25 Beats $0.19 Estimate, Sales $77.705M Beat $77.390M Estimate
Aurinia Pharmaceuticals (NASDAQ:AUPH) reported quarterly earnings of $0.25 per share which beat the analyst consensus estimate of $0.19 by 31.58 percent. This is a 56.25 percent increase over earnings of $0.16 per share
05-07 20:14
Aurinia to buy Kezar for USD 6.96 per share plus CVR
Aurinia to buy Kezar for USD 6.96 per share plus CVR Aurinia Pharmaceuticals agreed to acquire Kezar Life Sciences for USD 6.96 per share in cash. Deal includes a non-transferable contingent value right tied to zetomipzomib development milestones and select asset-related proceeds. Aurinia plans to l
03-30 20:34
Aurinia Pharmaceuticals Signs Agreement To Acquire Kezar Life Sciences For $6.955/Share In Cash
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs, announced today it has entered into a
03-30 20:04
Why Aurinia Pharmaceuticals Stock Is Surging Monday Morning
Aurinia Pharmaceuticals shares are trading higher Monday after announcing a leadership transition seen as a sign of continuity and strategy.
03-23 22:26
Aurinia Pharmaceuticals appoints Kevin Tang as CEO
Aurinia Pharmaceuticals (AUPH) announced on Monday that Kevin Tang, Aurinia’s Chair of the Board, will succeed Peter Greenleaf as chief executive officer. The firm added that Greenleaf will continue a...
03-23 20:22
BRIEF-Aurinia Announces Management Transition
BRIEF-Aurinia Announces Management Transition Aurinia Pharmaceuticals Inc AUPH.O : AURINIA ANNOUNCES MANAGEMENT TRANSITION AURINIA PHARMACEUTICALS INC - APPOINTS KEVIN TANG AS CEO SUCCEEDING PETER GREENLEAF AURINIA PHARMACEUTICALS INC - APPOINTS MICHAEL HEARNE AS CFO Source text: ID:nBw2qBQjSa Furth
03-23 20:08
Earnings Breakdown: Aurinia Pharmaceuticals Q4
Aurinia Pharmaceuticals (NASDAQ:AUPH) reported its Q4 earnings results on Thurs...
02-26 21:56
